BFRI Stock Analysis: Buy, Sell, or Hold?
BFRI - Biofrontera Inc. Common Stock
$1.48
0.00 (0.00%)
▲
5d:
+13.85%
30d:
+35.78%
90d:
+89.94%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When BFRI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BFRI is 14.7% above its trading range ($1.29). Market expects -11.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BFRI is 14.7% above its trading range ($1.29). Market expects -11.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.95
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$1.83
19.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 4.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BFRI is currently trading at $1.48, which is considered extended relative to its 30-day fair value range of $1.08 to $1.29. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.4) compared to its historical average (4.9). Remarkably, the market is currently pricing in an annual earnings decline of 11.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BFRI is in a strong uptrend. The price is approaching resistance at $1.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BFRI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+305.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BFRI is in a strong uptrend. The price is approaching resistance at $1.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BFRI scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+305.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.08 -
$1.29
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
19.0%
All Signals
- BEARISH: Price significantly overextended (+14.7% above its trading range)
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 305.4% below Wall St target ($6.00)
- WARNING: Composite score 39/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.29
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.18
Resistance Level
$1.52
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.44
Wall Street Target
$6.00
(+305.4%)
Revenue Growth (YoY)
32.9%
Profit Margin
-13.8%
Valuation Discount vs History
-11.0% cheaper
PE vs Historical
3.4 vs 4.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.0%
(market-implied from PE analysis)
1-Year Target
$1.33
(-10%)
2-Year Target
$1.20
(-19%)
3-Year Target
$1.08
(-27%)
3-Yr Target (if PE normalizes)
(PE: 3→5)
$1.54
(+4%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.4 to 4.9
Stabilization Target:
$2.11
(+42.4%)
PE Expansion Potential:
+42.4%
Share & Embed Analysis
Last updated: August 22, 2026 8:24 PM ET
Data refreshes hourly during market hours. Next update: 9:24 PM
Data refreshes hourly during market hours. Next update: 9:24 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BFRI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 56 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 43 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$653 | 48 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 55 HOLD |
